TRCT
VRCA icon

Tower Research Capital (TRC)’s Verrica Pharmaceuticals VRCA Stock Holding History

Tower Research Capital (TRC)’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.53K Sell
856
-2,486
-74% -$15.9K ﹤0.01% 4188
2025
Q4 		$27.8K Buy
3,342
+1,799
+117% +$9.97K ﹤0.01% 2857
2025
Q3 		$6.65K Sell
1,543
-1,146
-43% -$6.91K ﹤0.01% 4147
2025
Q2 		$14.3K Buy
2,689
+1,165
+76% +$6.27K ﹤0.01% 3842
2025
Q1 		$6.74K Buy
1,524
+426
+39% +$2.75K ﹤0.01% 4017
2024
Q4 		$7.68K Buy
1,098
+493
+81% +$5.42K ﹤0.01% 4056
2024
Q3 		$8.77K Buy
605
+136
+29% +$6.13K ﹤0.01% 3933
2024
Q2 		$34.2K Buy
469
+316
+207% +$24.3K ﹤0.01% 3386
2024
Q1 		$9.04K Sell
153
-51
-25% -$2.81K ﹤0.01% 3911
2023
Q4 		$15K Sell
204
-177
-46% -$7.27K ﹤0.01% 3847
2023
Q3 		$14.8K Buy
381
+229
+151% +$11.6K ﹤0.01% 3656
2023
Q2 		$8.75K Sell
152
-645
-81% -$39.2K ﹤0.01% 4377
2023
Q1 		$51K Buy
797
+161
+25% +$9.74K ﹤0.01% 2483
2022
Q4 		$18K Sell
636
-69
-10% -$1.84K ﹤0.01% 3240
2022
Q3 		$21K Buy
705
+51
+8% +$1.75K ﹤0.01% 3910
2022
Q2 		$12K Sell
654
-1,322
-67% -$66.4K ﹤0.01% 4318
2022
Q1 		$160K Buy
1,976
+399
+25% +$32.9K ﹤0.01% 1899
2021
Q4 		$144K Buy
1,577
+1,500
+1,948% +$170K ﹤0.01% 1995
2021
Q3 		$10K Sell
77
-159
-67% -$17.8K ﹤0.01% 4345
2021
Q2 		$27K Sell
236
-93
-28% -$11.3K ﹤0.01% 3615
2021
Q1 		$50K Sell
329
-153
-32% -$21.2K ﹤0.01% 3131
2020
Q4 		$56K Sell
482
-1,133
-70% -$104K ﹤0.01% 3002
2020
Q3 		$125K Buy
1,615
+1,348
+505% +$110K ﹤0.01% 2968
2020
Q2 		$29K Buy
+267
New +$30.9K ﹤0.01% 3467
2020
Q1 		– Sell
-26
Closed -$4K – 3966
2019
Q4 		$4K Sell
26
-14
-35% -$2.07K ﹤0.01% 2827
2019
Q3 		$6K Buy
+40
New +$4.46K ﹤0.01% 3250
2019
Q2 		– Sell
-25
Closed -$3K – 4357
2019
Q1 		$3K Sell
25
-68
-73% -$7.84K ﹤0.01% 3326
2018
Q4 		$8K Sell
93
-166
-64% -$20.2K ﹤0.01% 2640
2018
Q3 		$42K Buy
+259
New +$44.2K ﹤0.01% 1876

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tower Research Capital (TRC)'s VRCA Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Verrica Pharmaceuticals (VRCA) stake by 74% in Q1 2026, selling an estimated $15.9K and leaving 856 shares worth $4.53K. The position accounts for ﹤0.01% of the portfolio, ranked #4188.

Tower Research Capital (TRC) first reported a position in VRCA in Q3 2018 and has held it in 29 quarters since. The position peaked at $160K in Q1 2022. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

  • Tower Research Capital (TRC) held 856 shares of Verrica Pharmaceuticals worth $4.53K as of Q1 2026.
  • Tower Research Capital (TRC) sold 2,486 Verrica Pharmaceuticals shares in Q1 2026, an estimated $15.9K.
  • Verrica Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4188 holding.
  • Tower Research Capital (TRC) first reported a position in Verrica Pharmaceuticals in Q3 2018 and has held it in 29 quarters since.
  • Tower Research Capital (TRC)'s Verrica Pharmaceuticals position peaked at $160K in Q1 2022.
  • 39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.